Urogen Pharma Ltd
URGN21.350USD
+0.830+4.04%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
998.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Urogen Pharma Ltd Unternehmen
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd Informationen
BörsenkürzelURGN
Name des UnternehmensUrogen Pharma Ltd
IPO-datumMay 04, 2017
CEOBarrett (Elizabeth A)
Anzahl der mitarbeiter235
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse9 Ha'ta'asiya St
StadtRA'ANANA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl4365007
Telefon97297707601
Websitehttps://www.urogen.com/
BörsenkürzelURGN
IPO-datumMay 04, 2017
CEOBarrett (Elizabeth A)
Führungskräfte von Urogen Pharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Andere
64.52%
Aktionäre
Aktionäre
Anteil
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
Andere
64.52%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
29.37%
Research Firm
22.98%
Investment Advisor
22.01%
Investment Advisor/Hedge Fund
19.50%
Insurance Company
4.14%
Individual Investor
2.09%
Corporation
1.79%
Private Equity
1.47%
Bank and Trust
0.25%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
320
48.56M
103.75%
-13.57M
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RTW Investments L.P.
4.54M
9.71%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
4.22M
9.01%
+1.88M
+80.79%
Sep 30, 2025
TD Securities, Inc.
3.19M
6.82%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.46M
5.25%
+983.01K
+66.65%
Sep 30, 2025
Jefferies LLC
2.20M
4.7%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.58%
+33.75K
+1.60%
Sep 30, 2025
SilverArc Capital Management, LLC
1.58M
3.37%
-445.20K
-22.01%
Sep 30, 2025
Millennium Management LLC
1.47M
3.14%
+874.71K
+147.25%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.32M
2.82%
--
--
Jan 31, 2025
Acorn Capital Advisors, LLC
1.26M
2.69%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
Mehr Anzeigen
ARK Israel Innovative Technology ETF
Anteil2.09%
Tema Oncology ETF
Anteil1.92%
ALPS Medical Breakthroughs ETF
Anteil0.39%
Hypatia Women CEO ETF
Anteil0.28%
ProShares Ultra Nasdaq Biotechnology
Anteil0.16%
iShares Micro-Cap ETF
Anteil0.15%
Fidelity Enhanced Small Cap ETF
Anteil0.11%
Vanguard US Momentum Factor ETF
Anteil0.1%
Invesco Nasdaq Biotechnology ETF
Anteil0.09%
iShares Biotechnology ETF
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
